<DOC>
	<DOC>NCT03035279</DOC>
	<brief_summary>This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC), and consists of Part A (dose regimen finding), followed by Part B (dose expansion). Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and schedule. Part B (dose expansion) will enroll additional participants who will be treated with a study drug dose at or below the MTD determined in Part A.</brief_summary>
	<brief_title>A Study of SC-006 in Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Participants with histologically or cytologically confirmed advanced metastatic or unresectable colorectal cancer (CRC) that is relapsed, refractory, or progressive following at least 2 prior systemic regimens in the metastatic setting. Participants with an Eastern Cooperative Oncology Group (ECOG) of 0 1. Participants with adequate hematologic, hepatic, and renal function. Participants with prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced colorectal cancer</keyword>
	<keyword>Unresectable colorectal cancer</keyword>
	<keyword>Maximum tolerated dose</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>